36 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
11
Ending by 2030
Dec 2026
Next term end
16
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Sep 2029 · Medium confidence
Also notable
Ends Feb 2036 · Medium confidence
Also notable
Ends Dec 2035 · Medium confidence
Pharmaceutical Compositions and Related Methods of Delivery
US 11,400,159
Cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Method of Treating Diseases
US 11,338,011
Cited by 11 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2036. A terminal disclaimer caps this term to an earlier patent's.
Oral Octreotide Administered in Combination with Other Therapeutic Agents
US 10,682,387
Cited by 14 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2035.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Methods of Detecting Anti-Leptin Neutralizing Antibodies (US 11,709,166) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Betulin-Containing Birch Bark Extracts and Their Formulation (US 11,826,374) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Jul 2, 2027The maintenance fee for Method of Treating Diseases (US 11,857,595) comes due Jul 2, 2027. Unpaid by Jan 3, 2028, it lapses early.
- 2 fees due Aug 6 to 23, 2027 · next Aug 6
- 1 fee due Oct 30, 2027The maintenance fee for Pharmaceutical Compositions and Related Methods of Delivery (US 11,969,471) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 16 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Method of Treating Diseases | 8 in force | to Feb 2036 |
| Pharmaceutical Compositions and Related Methods of Delivery | 7 in force | to Sep 2029 |
| Betulin-Containing Birch Bark Extracts and Their Formulation | 4 in force | to Jan 2039 |
| Oral Octreotide Therapy and Contraceptive Methods | 2 in force | to Dec 2040 |
| Methods of Detecting Anti-Leptin Neutralizing Antibodies | 2 in force | to May 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,536,380 | Triterpene-Containing Oleogel-Forming Agent, Triterpene-Containing Oleogel and Method for Producing a Triterpene-Containing Oleogel In force · High confidence | In force | High confidence | |
| US 8,241,670 | Compositions Capable of Facilitating Penetration Across a Biological Barrier In force · High confidence | In force | High confidence | |
| US 8,329,198 | Pharmaceutical Compositions and Related Methods of Delivery In force · Low confidence | In force | Low confidence | |
| US 8,535,695 | Pharmaceutical Compositions and Related Methods of Delivery In force · Low confidence | In force | Low confidence | |
| US 9,265,812 | Pharmaceutical Compositions and Related Methods of Delivery In force · Low confidence | In force | Low confidence | |
| US 9,566,246 | Pharmaceutical Compositions and Related Methods of Delivery In force · Medium confidence | In force | Medium confidence | |
| US 11,400,159 | Pharmaceutical Compositions and Related Methods of Delivery In force · Medium confidence | In force | Medium confidence | |
| US 11,969,471 | Pharmaceutical Compositions and Related Methods of Delivery In force · Medium confidence | In force | Medium confidence | |
| US 11,986,529 | Pharmaceutical Compositions and Related Methods of Delivery In force · Medium confidence | In force | Medium confidence | |
| US 9,352,041 | Use of an Oleogel Containing Triterpene for Healing Wounds In force · High confidence | In force | High confidence |
Also on record, not counted in the 36: 2 patents ended · 11 applications pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.